ROBOSENSE
22.8.2019 16:57:11 CEST | Business Wire | Press release
RoboSense, the leading supplier of LiDAR perception system solutions, and Aidrivers, the UK's leading provider of autonomous mobility solutions for industrial applications announced today a partnership in system integration. Aidrivers will integrate RoboSense Smart LiDAR Sensor System into their own Autonomous Driving Systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005468/en/
Aidrivers is delivering a fully autonomous natural navigation system that meets industrial safety standards to seaports, particularly for horizontal transportation, aimed for improving operation efficiency and leading the way in industrial autonomous mobility automation. Their solution can work under all harsh weather conditions by achieving true 3D mapping and localization for precision positioning and situation cognisance and they are using RoboSense 3D LiDAR sensor technology, which collects stable and reliable environment information at near and far distance and under different weather conditions.
“ The performance of RoboSense 3D LiDAR products in harsh weather condition is impressive. We have been testing trailer vehicles under heavy rain and harsh weather conditions and our precision positioning system based on true 3D mapping and localization systems provides accurate localization result. The point cloud data quality in rainy days is excellent and outperforming state of the art.” Aidrivers founder and CEO Dr. Rafiq Swash said, “Aidrivers is dedicated to providing safer, reliable and high-quality Ai enabled autonomous mobility solutions for industrial transportation, and the partnership with RoboSense will give a great confidence to our end users that we are providing autonomous solutions which overcome current challenges of industrial horizontal transportation. Our Ai enabled autonomous solutions are now catering to more industrial transportation industries for both indoor and outdoor in complex environment and weather conditions.”
As one of the pioneer companies to commercialize autonomous driving technology in UK, Aidrivers has been favored by industry giants in the field of autonomous port automation. Aidrivers is deploying a fleet of autonomous prime movers for the world’s leading and busiest port terminals. Aidrivers and SANY have recently partnered to deliver autonomous electric vehicles, specifically industrial horizontal transport solutions, for the Chinese market.
Video about Aidrivers and SANY’s vehicle : https://twitter.com/aidriversltd/status/1141257250629177344?s=20
In these projects, the AI enabled autonomous mobility solutions provided by Aidrivers use RoboSense's 3D LiDARs to collect rich and reliable environment perception data, conduct real-time accurate 3D object detection and tracking. Aidrivers is leading the situation cognisance with AI enabled data fusion to deliver a safer and reliable autonomous driving solutions for complex trailer vehicles under harsh weather.
“Aidrivers is driving the commercialization of autonomous driving technology for industrial transportation on a global scale. RoboSense is very pleased to collaborate with Aidrivers to build safer and robust autonomous driving solutions for major port terminals, and push for the commercialization of this technology.” RoboSense Co-founder and COO, Mark said, “Through in-depth cooperation with Aidrivers, RoboSense will continue to explore and understand the needs of industrial automation, and together with our partners, we will optimize and launch more practical LiDAR perception systems from the application perspective. ”
RoboSense's LiDAR sensors, AI Perception Algorithms and Smart LiDAR Sensor System are widely used in various types of autonomous driving scenarios. Currently, RoboSenses partners covers the world's major autonomous driving technology companies, automotive OEMs, and Tier 1 suppliers. RoboSense has always striven to optimize product performance and reliability to help autonomous driving vehicles to better cope with harsh environments and extreme conditions.
For more information please visit https://aidrivers.ai/ and https://www.robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190822005468/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom